Affordable Access

deepdyve-link
Publisher Website

Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.

Authors
  • Reich, K1
  • Papp, K A2
  • Armstrong, A W3
  • Wasfi, Y4
  • Li, S4
  • Shen, Y K4
  • Randazzo, B4
  • Song, M4
  • Kimball, A B5
  • 1 Dermatologikum Berlin and SCIderm Research Institute, Hamburg, Germany. , (Germany)
  • 2 K Papp Clinical Research and Probity Research, Inc., Waterloo, Canada. , (Canada)
  • 3 University of Southern California, Los Angeles, CA, U.S.A.
  • 4 Janssen Research & Development, LLC, Spring House, PA, U.S.A.
  • 5 Harvard Medical School and Beth Israel Deaconess Medical Center, Inc., Boston, MA, U.S.A. , (Israel)
Type
Published Article
Journal
British Journal of Dermatology
Publisher
Wiley (Blackwell Publishing)
Publication Date
May 01, 2019
Volume
180
Issue
5
Pages
1039–1049
Identifiers
DOI: 10.1111/bjd.17454
PMID: 30485400
Source
Medline
Language
English
License
Unknown

Abstract

Long-term evaluation is required to confirm the safety profile of newer biologic agents. To report on pooled safety data from the ongoing VOYAGE 1 (NCT02207231) and VOYAGE 2 (NCT02207244) trials through 100 weeks of follow-up. Patients were randomized to either guselkumab 100 mg at weeks 0 and 4 and every 8 weeks thereafter; placebo at weeks 0, 4, 12 followed by guselkumab 100 mg at weeks 16 and 20 and every 8 weeks thereafter; or adalimumab 80 mg at week 0, 40 mg at week 1, and 40 mg every 2 weeks thereafter. Patients who received adalimumab crossed over to guselkumab at week 52 (VOYAGE 1) and at/after week 28 based on clinical response (VOYAGE 2). Open-label extensions, in which all patients received guselkumab, started at week 52 (VOYAGE 1) and week 76 (VOYAGE 2). Rates of adverse events (AEs) per 100 patient-years (PYs) are presented through 100 weeks of follow-up. Through week 52, observed rates for guselkumab- and adalimumab-treated patients, respectively, were 262·45 per 100 PYs and 328·28 per 100 PYs for AEs, 6·20 per 100 PYs and 7·77 per 100 PYs for serious AEs (SAEs), 1·22 per 100 PYs and 1·79 per 100 PYs for serious infections (SIs), 0·28 per 100 PYs and 0·40 per 100 PYs for malignancies other than nonmelanoma skin cancers (NMSCs), 0·56 per 100 PYs and 0·40 per 100 PYs for NMSCs, and 0·47 per 100 PYs and 0·40 per 100 PYs for major adverse cardiovascular events (MACEs). Rates among patients treated with guselkumab through week 52 and week 100, respectively, were 262·45 per 100 PYs and 210·41 per 100 PYs for AEs, 6·20 and 6·29 per 100 PYs, for SAEs, 1·22 per 100 PYs and 1·06 per 100 PYs for SIs, 0·28 per 100 PYs and 0·38 per 100 PYs for malignancies, 0·56 per 100 PYs and 0·39 per 100 PYs for NMSCs, and 0·47 per 100 PYs and 0·38 per 100 PYs for MACEs. Among patients treated with adalimumab, rates of AEs, SAEs, SIs, malignancies, NMSCs, and MACEs showed some variability before and after crossover to guselkumab, although no new safety signals were noted after crossover. The safety profile for guselkumab remains favourable through 100 weeks of treatment in patients with moderate-to-severe psoriasis. © 2018 British Association of Dermatologists.

Report this publication

Statistics

Seen <100 times